Literature DB >> 9741837

The cardiovascular effects of porcine relaxin in Brattleboro rats.

L J Parry1, B C Wilson, R S Poterski, A J Summerlee.   

Abstract

The effects of porcine relaxin on arterial blood pressure, heart rate, and the release of vasopressin and oxytocin were investigated in homozygous diabetes insipidus (di/di) Brattleboro and Long-Evans rats. Acute iv injection of relaxin (5 microg) caused a significant increase in mean arterial, systolic and diastolic blood pressures in Long-Evans rats compared with control injections of saline, but had no pressor effect in Brattleboro rats. Circulating concentrations of vasopressin were also significantly elevated above baseline in the Long-Evans rats 1 min after relaxin treatment, but remained undetectable in the relaxin-treated Brattleboro rats. Relaxin increased heart rate in both groups of animals 4 min after injection. The chronotropic effect of relaxin was, however, attenuated in the Brattleboro rats. Intravenous relaxin injection also caused a significant increase in plasma oxytocin concentrations 5 min posttreatment in both the Long-Evans and Brattleboro rats. The change in plasma oxytocin above basal concentrations was significantly greater in Brattleboro rats compared with Long-Evans controls. The data in this study demonstrate that iv relaxin increases heart rate, but not arterial blood pressure in Brattleboro rats. Furthermore, the relaxin-induced release of oxytocin in Brattleboro rats does not result in an acute pressor response.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9741837     DOI: 10.1385/ENDO:8:3:317

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  33 in total

1.  Relaxin inhibits the pulsatile release of oxytocin but increases basal concentrations of hormone in lactating rats.

Authors:  A J Summerlee; K T O'Byrne; R S Poterski
Journal:  Biol Reprod       Date:  1998-04       Impact factor: 4.285

2.  Lack of evidence of a vasodepressor role for relaxin in spontaneously hypertensive and normotensive pregnant rats.

Authors:  R A Ahokas; B M Sibai; G D Anderson
Journal:  Am J Obstet Gynecol       Date:  1989-09       Impact factor: 8.661

3.  Lesion of the subfornical organ affects the haemotensive response to centrally administered relaxin in anaesthetized rats.

Authors:  A D Mumford; L J Parry; A J Summerlee
Journal:  J Endocrinol       Date:  1989-09       Impact factor: 4.286

4.  The dipsogenic effects of rat relaxin: The effect of photoperiod and the potential role of relaxin on drinking in pregnancy.

Authors:  A J Summerlee; D J Hornsby; D G Ramsey
Journal:  Endocrinology       Date:  1998-05       Impact factor: 4.736

5.  Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart.

Authors:  M Toth; P Taskinen; H Ruskoaho
Journal:  J Endocrinol       Date:  1996-09       Impact factor: 4.286

Review 6.  The emerging concept of relaxin as a centrally acting peptide hormone with hemodynamic actions.

Authors:  B J Geddes; A J Summerlee
Journal:  J Neuroendocrinol       Date:  1995-06       Impact factor: 3.627

7.  Neutralization of relaxin within the brain affects the timing of birth in rats.

Authors:  A J Summerlee; D G Ramsey; R S Poterski
Journal:  Endocrinology       Date:  1998-02       Impact factor: 4.736

8.  Changes in water and electrolyte balance, plasma volume and composition during pregnancy in the rat.

Authors:  J C Atherton; J M Dark; H O Garland; M R Morgan; J Pidgeon; S Soni
Journal:  J Physiol       Date:  1982-09       Impact factor: 5.182

9.  Cardiac effects of relaxin in rats.

Authors:  H Kakouris; L W Eddie; R J Summers
Journal:  Lancet       Date:  1992-05-02       Impact factor: 79.321

10.  The specificity of angiotensin II receptor binding in rat brain.

Authors:  F E Cole; H L Blakesley; K A Graci; E D Frohlich; A A MacPhee
Journal:  Peptides       Date:  1981       Impact factor: 3.750

View more
  1 in total

1.  Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290.

Authors:  Elena M Kaftanovskaya; Mariluz Soula; Courtney Myhr; Brian A Ho; Stefanie N Moore; Changwon Yoo; Briana Cervantes; Javier How; Juan Marugan; Irina U Agoulnik; Alexander I Agoulnik
Journal:  J Endocr Soc       Date:  2017-05-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.